• Japanese
  • Korean
  • Chinese
Cover Image

Global Cancer Biomarkers Market 2015-2019

About Cancer Biomarkers

Biomarkers are molecules present in the blood, other body fluids such as serum, urine, or in tissue that are indicators of a disease or abnormal conditions. Biomarkers are mostly used as diagnostic tools. Biomarkers help in identifying potential drug failures in initial stages, leading to savings in time and costs. Biomarkers are becoming an essential part of the drug discovery process. Cancer Biomarkers are proteins or metabolites indicative of tumor state and progression characteristics. They are non-invasive, enable high speed cancer diagnosis and also enhance early cancer detection and screening. The best example of a cancer biomarker is that of prostate specific antigen. PSA is measured in the blood to screen for and monitor treatment for prostate cancer. PSA, as a biomarker helps the doctors to monitor the progress of the cancer. It also helps to evaluate the response of the cancer to the treatment therapy.

TechNavio's analysts forecast the Global Cancer Biomarkers market to grow at a CAGR of 18.26 percent over the period 2014-2019.

Covered in this Report

TechNavio's report, Global Cancer Biomarkers Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Cancer Biomarkers market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Abbott Laboratories
  • Affymetrix
  • Illumina
  • Qiagen
  • Quest Diagnostics
  • Roche Diagnostics

Other Prominent Vendors

  • Agendia
  • Agilent Technologies
  • Alere
  • Ambry Genetics
  • Amgen
  • Astellas Pharma US
  • Astex Pharmaceuticals
  • Atossa Genetics
  • Beckman Coulter
  • Becton, Dickinson and Company
  • Biocurex
  • bioMerieux
  • Celldex Therapeutics
  • Clarient
  • diaDexus
  • DiagnoCure
  • Epigenomics
  • EUSA Pharma
  • Exact Sciences
  • Foundation Medicine
  • Fujirebio Diagnostics
  • Genomic Health
  • Geron
  • Immunomedics
  • Morphotek
  • Myriad Genetics
  • Nodality
  • Northwest Biotherapeutics
  • Ocimum Biosolutions
  • Oncothyreon
  • OriGene
  • Polymedco
  • Radient Pharmaceuticals
  • Randox Laboratories
  • Siemens Healthcare
  • US Biomarkers
  • Vermillion

Market Driver

  • Increased Prevalence of Cancer
  • For a full, detailed list, view our report

Market Challenge

  • Regulatory and Reimbursement Issues
  • For a full, detailed list, view our report

Market Trend

  • Growing Popularity of Companion Diagnostics
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Incidence and Prevalence

08. Biomarkers Used in Cancer Diagnosis

    • 08.1.1. Cancer Biomarkers : FDA Approved till 2012
    • 08.1.2. Cancer Biomarkers : FDA Approved 2013

09. FDA Approval Process for Protein-Based Cancer Biomarkers

10. Geographical Segmentation

  • 10.1. Cancer Biomarkers Market in the Americas
    • 10.1.1. Market Size and Forecast
    • 10.1.2. Cancer Biomarkers Market in US
  • 10.2. Cancer Biomarkers Market in the EMEA Region
    • 10.2.1. Market Size and Forecast
  • 10.3. Cancer Biomarkers Market in APAC Region
    • 10.3.1. Market Size and Forecast

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Vendor Analysis 2014
  • 18.3. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. Abbott Laboratories
    • 19.1.1. Key Facts
    • 19.1.2. Business Description
    • 19.1.3. Business Segmentation
    • 19.1.4. Business Strategy
    • 19.1.5. Revenue by Business Segmentation
    • 19.1.6. Revenue Comparison 2011 and 2012
    • 19.1.7. Revenue by Geographical Segmentation
    • 19.1.8. Key Information
    • 19.1.9. SWOT Analysis
  • 19.2. Affymetrix
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Business Segmentation
    • 19.2.4. Business Segmentation by Revenue 2013
    • 19.2.5. Business Segmentation by Revenue 2012 and 2013
    • 19.2.6. Sales by Geography
    • 19.2.7. Business Strategy
    • 19.2.8. Key Information
    • 19.2.9. SWOT Analysis
  • 19.3. Illumina
    • 19.3.1. Key Facts
    • 19.3.2. Business Overview
    • 19.3.3. Business Segmentation
    • 19.3.4. Geographical Segmentation by Revenue 2013
    • 19.3.5. Business Strategy
    • 19.3.6. Key Information
    • 19.3.7. SWOT Analysis
  • 19.4. Qiagen
    • 19.4.1. Key Facts
    • 19.4.2. Business Overview
    • 19.4.3. Product Segmentation by Revenue 2013
    • 19.4.4. Product Segmentation by Revenue 2012 and 2013
    • 19.4.5. Geographical Segmentation by Revenue 2013
    • 19.4.6. Business Strategy
    • 19.4.7. Recent Developments
    • 19.4.8. SWOT Analysis
  • 19.5. Quest Diagnostics
    • 19.5.1. Key Facts
    • 19.5.2. Business Overview
    • 19.5.3. Business Segmentation by Revenue 2013
    • 19.5.4. Business Segmentation by Revenue 2011-2013
    • 19.5.5. Geographical Segmentation by Revenue 2013
    • 19.5.6. Business Strategy
    • 19.5.7. Recent Developments
    • 19.5.8. SWOT Analysis
  • 19.6. Roche Diagnostics
    • 19.6.1. Key Facts
    • 19.6.2. Business Overview
    • 19.6.3. Business Segmentation by Revenue 2013
    • 19.6.4. Geographical Segmentation by Revenue 2013
    • 19.6.5. Business Strategy
    • 19.6.6. Key Developments
    • 19.6.7. SWOT Analysis

20. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Cancer Biomarkers Market 2014-2019 (US$ billion)
  • Exhibit 3: Incidence of Various Types of Cancer in 2012
  • Exhibit 4: FDA Classification of Medical Devices by Type of Class
  • Exhibit 5: Global Cancer Biomarkers Market by Geographical Segmentation 2014
  • Exhibit 6: Global Cancer Biomarkers Market by Geographical Segmentation 2019
  • Exhibit 7: Cancer Biomarkers Market in the Americas 2014-2019 (US$ billion)
  • Exhibit 8: Cancer Biomarkers Market in US 2014-2019 (US$ billion)
  • Exhibit 9: Cancer Biomarkers Market in the EMEA Region 2014-2019 (US$ billion)
  • Exhibit 10: Cancer Biomarkers Market in the APAC Region 2014-2019 (US$ billion)
  • Exhibit 11: Global Cancer Biomarkers Market by Geographical Segmentation 2014-2019
  • Exhibit 12: Abbott Laboratories Inc.: Business Segmentation
  • Exhibit 13: Abbott Laboratories Inc.: Revenue by Business Segmentation 2012
  • Exhibit 14: Abbott Laboratories Inc.: Revenue by Business Segmentation 2011 and 2012 (US$ million)
  • Exhibit 15: Abbott Laboratories Inc.: Revenue by Geographical Segmentation 2012
  • Exhibit 16: Affymetrix Inc.: Business Segmentation 2013
  • Exhibit 17: Affymetrix Inc.: Business Segmentation by Revenue 2013
  • Exhibit 18: Affymetrix Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 19: Affymetrix Inc.: Sales by Geography 2013
  • Exhibit 20: Illumina: Business Segmentation
  • Exhibit 21: Illumina: Geographical Segmentation by Revenue 2013
  • Exhibit 22: Qiagen: Product Segmentation by Revenue 2013
  • Exhibit 23: Qiagen: Product Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 24: Qiagen: Geographical Segmentation by Revenue 2013
  • Exhibit 25: Global Cancer Biomarkers Market: Business Segmentation by Revenue 2013
  • Exhibit 26: Global Cancer Biomarkers Market: Business Segmentation by Revenue 2011-2013 (US$ billion)
  • Exhibit 27: Global Cancer Biomarkers Market: Geographical Segmentation by Revenue 2013
  • Exhibit 28: Roche Diagnostics: Business Segmentation by Revenue 2013
  • Exhibit 29: Roche Diagnostics: Geographical Segmentation by Revenue 2013
Show More
Pricing
  • Int'l: +1-860-674-8796
  • TollFree(US): +1-866-353-3335
  • Europe: +32-2-535-7543
  • Asia: +65-6223-2436
Back to Top